Dysregulated intracellular signaling in the striatum in a pathophysiologically grounded model of Tourette syndrome

European Neuropsychopharmacology

Volumn 24, Issue 12, 2014, Pages 1896-1906

  Rapanelli, Maximiliano ^a,b   Frick, Luciana R ^a,b   Pogorelov, Vladimir ^a,b,e   Ota, Kristie T ^a,b   Abbasi, Eeman ^a,b   Ohtsu, Hiroshi ^d   Pittenger, Christopher ^a,b,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TOHOKU UNIVERSITY   (Japan)

^e DUKE UNIVERSITY   (United States)

Author keywords

Basal ganglia; Dopamine; Histamine; Striatum; Tourette syndrome

Indexed keywords

AMPHETAMINE; DOPAMINE; GLYCOGEN SYNTHASE KINASE 3BETA; HISTAMINE; HISTIDINE DECARBOXYLASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MTOR PROTEIN, MOUSE; ONCOPROTEIN; PROTEIN S6; RIBOSOMAL PROTEIN S6, MOUSE; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVATION; GENE INACTIVATION; GENE MUTATION; GENOTYPE; GILLES DE LA TOURETTE SYNDROME; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALE; MICRODIALYSIS; MOUSE; NERVE CELL; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

AMPHETAMINE; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; GLYCOGEN SYNTHASE KINASE 3; HISTIDINE DECARBOXYLASE; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, KNOCKOUT; NEURONS; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; RIBOSOMAL PROTEIN S6; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TOURETTE SYNDROME;

EID: 84918799346     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.10.007     Document Type: Article

References (50)

1. Albin R.L., Mink J.W. Recent advances in Tourette syndrome research. Trends Neurosci. 2006, 29:175-182.
2. Bateup H.S., Svenningsson P., Kuroiwa M., Gong S., Nishi A., Heintz N., Greengard P. Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat. Neurosci. 2008, 11:932-939.
3. Baym C.L., Corbett B.A., Wright S.B., Bunge S.A. Neural correlates of tic severity and cognitive control in children with Tourette syndrome. Brain: a journal of neurology 2008, 131:165-179.
4. Beaulieu J.M., Gainetdinov R.R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 2011, 63:182-217.
5. Beaulieu J.M., Gainetdinov R.R., Caron M.G. Akt/GSK3 signaling in the action of psychotropic drugs. Annu. Rev. Pharmacol. Toxicol. 2009, 49:327-347.
6. Beaulieu J.M., Sotnikova T.D., Marion S., Lefkowitz R.J., Gainetdinov R.R., Caron M.G. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005, 122:261-273.
7. Beaulieu J.M., Sotnikova T.D., Yao W.D., Kockeritz L., Woodgett J.R., Gainetdinov R.R., Caron M.G. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:5099-5104.
8. Beaulieu J.M., Tirotta E., Sotnikova T.D., Masri B., Salahpour A., Gainetdinov R.R., Borrelli E., Caron M.G. Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J. Neurosci.: the official journal of the Society for Neuroscience 2007, 27:881-885.
9. Bertran-Gonzalez J., Bosch C., Maroteaux M., Matamales M., Herve D., Valjent E., Girault J.A. Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol. J. Neurosci.: the official journal of the Society for Neuroscience 2008, 28:5671-5685.
10. Bloch M.H. Emerging treatments for Tourette's disorder. Curr. Psychiatry Rep. 2008, 10:323-330.
11. Brami-Cherrier K., Valjent E., Herve D., Darragh J., Corvol J.C., Pages C., Arthur S.J., Girault J.A., Caboche J. Parsing molecular and behavioral effects of cocaine in mitogen- and stress-activated protein kinase-1-deficient mice. J. Neurosci.: the official journal of the Society for Neuroscience 2005, 25:11444-11454.
12. Castellan Baldan L., Williams K.A., Gallezot J.D., Pogorelov V., Rapanelli M., Crowley M., Anderson G.M., Loring E., Gorczyca R., Billingslea E., et al. Histidine decarboxylase deficiency causes Tourette syndrome: parallel findings in humans and mice. Neuron 2014, 81:77-90.
13. Chiang G.G., Abraham R.T. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J. Biol. Chem. 2005, 280:25485-25490.
14. Davis L.K., Yu D., Keenan C.L., Gamazon E.R., Konkashbaev A.I., Derks E.M., Neale B.M., Yang J., Lee S.H., Evans P., et al. Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLos Genet. 2013, 9:e1003864.
15. Dere E., De Souza-Silva M.A., Topic B., Spieler R.E., Haas H.L., Huston J.P. Histidine-decarboxylase knockout mice show deficient nonreinforced episodic object memory, improved negatively reinforced water-maze performance, and increased neo- and ventro-striatal dopamine turnover. Learn. Memory 2003, 10:510-519.
16. Ellender T.J., Huerta-Ocampo I., Deisseroth K., Capogna M., Bolam J.P. Differential modulation of excitatory and inhibitory striatal synaptic transmission by histamine. J. Neurosci.: the official journal of the Society for Neuroscience 2011, 31:15340-15351.
17. Emamian E.S., Hall D., Birnbaum M.J., Karayiorgou M., Gogos J.A. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet. 2004, 36:131-137.
18. Ercan-Sencicek A.G., Stillman A.A., Ghosh A.K., Bilguvar K., O'Roak B.J., Mason C.E., Abbott T., Gupta A., King R.A., Pauls D.L., et al. l-Histidine decarboxylase and Tourette's syndrome. N. Engl. J. Med. 2010, 362:1901-1908.
19. Fernandez T.V., Sanders S.J., Yurkiewicz I.R., Ercan-Sencicek A.G., Kim Y.S., Fishman D.O., Raubeson M.J., Song Y., Yasuno K., Ho W.S., et al. Rare copy number variants in Tourette syndrome disrupt genes in histaminergic pathways and overlap with autism. Biol. Psychiatry 2012, 71:392-402.
20. Frodin M., Gammeltoft S. Role and regulation of 90kDa ribosomal S6 kinase (RSK) in signal transduction. Mol. Cell. Endocrinol. 1999, 151:65-77.
21. Gerfen C.R., Miyachi S., Paletzki R., Brown P. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J. Neurosci.the official journal of the Society for Neuroscience 2002, 22:5042-5054.
22. Gerfen C.R., Paletzki R., Worley P. Differences between dorsal and ventral striatum in Drd1a dopamine receptor coupling of dopamine- and cAMP-regulated phosphoprotein-32 to activation of extracellular signal-regulated kinase. J. Neurosci.: the official journal of the Society for Neuroscience 2008, 28:7113-7120.
23. Girault J.A., Valjent E., Caboche J., Herve D. ERK2: a logical AND gate critical for drug-induced plasticity?. Curr. Opin. Pharmacol. 2007, 7:77-85.
24. Greengard P. The neurobiology of dopamine signaling. Biosci. Rep. 2001, 21:247-269.
25. Haas H.L., Sergeeva O.A., Selbach O. Histamine in the nervous system. Physiol. Rev. 2008, 88:1183-1241.
26. Hemmings B.A., Restuccia D.F. PI3K-PKB/Akt pathway. Cold Spring Harbor Perspect. Biol. 2012, 4:a011189.
27. Holz M.K., Blenis J. Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J. Biol. Chem. 2005, 280:26089-26093.
28. Jacinto E., Facchinetti V., Liu D., Soto N., Wei S., Jung S.Y., Huang Q., Qin J., Su B. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006, 127:125-137.
29. Karagiannidis I., Rizzo R., Tarnok Z., Wolanczyk T., Hebebrand J., Nothen M.M., Lehmkuhl G., Farkas L., Nagy P., Barta C., et al. Replication of association between a SLITRK1 haplotype and Tourette Syndrome in a large sample of families. Mol. Psychiatry 2012, 17:665-668.
30. Krusong K., Ercan-Sencicek A.G., Xu M., Ohtsu H., Anderson G.M., State M.W., Pittenger C. High levels of histidine decarboxylase in the striatum of mice and rats. Neurosci. Lett. 2011, 495:110-114.
31. Magnuson B., Ekim B., Fingar D.C. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem. J. 2012, 441:1-21.
32. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
33. Moreno E., Hoffmann H., Gonzalez-Sepulveda M., Navarro G., Casado V., Cortes A., Mallol J., Vignes M., McCormick P.J., Canela E.I., et al. Dopamine D1-histamine H3 receptor heteromers provide a selective link to MAPK signaling in GABAergic neurons of the direct striatal pathway. J. Biol. Chem. 2011, 286:5846-5854.
34. Moreno E., Moreno-Delgado D., Navarro G., Hoffmann H.M., Fuentes S., Rosell-Vilar S., Gasperini P., Rodriguez-Ruiz M., Medrano M., Mallol J., et al. Cocaine disrupts histamine H3 receptor modulation of dopamine D1 receptor signaling: sigma1-D1-H3 receptor complexes as key targets for reducing cocaine's effects. J. Neurosci.: the official journal of the Society for Neuroscience 2014, 34:3545-3558.
35. Nishi A., Kuroiwa M., Shuto T. Mechanisms for the modulation of dopamine d(1) receptor signaling in striatal neurons. Front. Neuroanat. 2011, 5:43.
36. Ohtsu H., Tanaka S., Terui T., Hori Y., Makabe-Kobayashi Y., Pejler G., Tchougounova E., Hellman L., Gertsenstein M., Hirasawa N., et al. Mice lacking histidine decarboxylase exhibit abnormal mast cells. FEBS Lett. 2001, 502:53-56.
37. Panula P., Nuutinen S. The histaminergic network in the brain: basic organization and role in disease. Nat. Rev. Neurosci. 2013, 14:472-487.
38. Paxinos G., Franklin K.B.J. The mouse brain in stereotaxic coordinates, Compact 2004, Elsevier Academic Press, Amsterdam; Boston. second ed.
39. Pillot C., Heron A., Cochois V., Tardivel-Lacombe J., Ligneau X., Schwartz J.C., Arrang J.M. A detailed mapping of the histamine H(3) receptor and its gene transcripts in rat brain. Neuroscience 2002, 114:173-193.
40. Pittenger C. Animal models of Tourette syndrome and obsessive-compulsive disorder. In Animal Models of Movement Disorders 2014, Elsevier, New York. M.E. LeDoux (Ed.).
41. Prickaerts J., Moechars D., Cryns K., Lenaerts I., van Craenendonck H., Goris I., Daneels G., Bouwknecht J.A., Steckler T. Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J. Neurosci.: the official journal of the Society for Neuroscience 2006, 26:9022-9029.
42. Robertson M.M., Eapen V., Cavanna A.E. The international prevalence, epidemiology, and clinical phenomenology of Tourette syndrome: a cross-cultural perspective. J. Psychosom. Res. 2009, 67:475-483.
43. Roux P.P., Shahbazian D., Vu H., Holz M.K., Cohen M.S., Taunton J., Sonenberg N., Blenis J. RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J. Biol. Chem. 2007, 282:14056-14064.
44. Singer H.S., Szymanski S., Giuliano J., Yokoi F., Dogan A.S., Brasic J.R., Zhou Y., Grace A.A., Wong D.F. Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. Am. J. Psychiatry 2002, 159:1329-1336.
45. State M.W. The genetics of Tourette disorder. Curr. Opin. Genet. Dev. 2011, 21:302-309.
46. Sutton L.P., Rushlow W.J. The effects of neuropsychiatric drugs on glycogen synthase kinase-3 signaling. Neuroscience 2011, 199:116-124.
47. Urs N.M., Snyder J.C., Jacobsen J.P., Peterson S.M., Caron M.G. Deletion of GSK3beta in D2R-expressing neurons reveals distinct roles for beta-arrestin signaling in antipsychotic and lithium action. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:20732-20737.
48. Valjent E., Pascoli V., Svenningsson P., Paul S., Enslen H., Corvol J.C., Stipanovich A., Caboche J., Lombroso P.J., Nairn A.C., et al. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:491-496.
49. Williams K., Bloch M.H., State M.W., Pittenger C. Tourette syndrome and tic disorders. In Neurobiology of Mental Illness 2013, Oxford, New York. fourth ed. D.S. Charney, J.D. Buxbaum, P. Sklar, E.J. Nestler (Eds.).
50. Wong D.F., Brasic J.R., Singer H.S., Schretlen D.J., Kuwabara H., Zhou Y., Nandi A., Maris M.A., Alexander M., Ye W., et al. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology 2008, 33:1239-1251.